Olfactory dysfunction in COVID-19: a marker of good prognosis?

Detalhes bibliográficos
Autor(a) principal: Mendonça,Cindy Vitalino
Data de Publicação: 2022
Outros Autores: Mendes Neto,José Arruda, Suzuki,Fabio Akira, Orth,Marlon Steffens, Machado Neto,Hugo, Nacif,Sérgio Roberto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Otorhinolaryngology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942022000300439
Resumo: Abstract Introduction In May 2020, the World Health Organization recognized olfactory dysfunction as a COVID-19 symptom. The presence of hyposmia/anosmia may be a marker of good prognosis in COVID-19. Objective To associate the presence of olfaction disorder to the clinical condition severity in patients with COVID-19. Methods Individuals with the flu syndrome caused by SARS-CoV-2, diagnosed from March to June 2020, were recruited. They were divided into three groups: mild flu syndrome, severe flu syndrome (admitted to hospital wards) and critical illness (admitted to the ICU). Inpatients were interviewed by telephone contact after hospital discharge and their medical records were also evaluated regarding complementary test results. Outpatients answered an electronic questionnaire containing only clinical information. Results A total of 261 patients participated in the study: 23.75% with mild flu syndrome, 57.85% with severe flu syndrome and 18.40% with critical illness. A total of 66.28% patients with COVID-19 had olfaction disorders. In approximately 56.58% of the individuals the smell alterations lasted between 9 days and 2 months. There was a significantly higher proportion of individuals with olfactory dysfunction in the group with mild flu syndrome than in the severe flu syndrome group (mild × severe - p< 0.001; Odds Ratio = 4.63; 95% CI [1.87-10.86]). This relationship was also maintained between patients with mild flu syndrome and critically-ill patients (mild × critical - p< 0.001; Odds Ratio = 9.28; 95% CI [3.52-25.53]). Conclusion Olfaction dysfunction was significantly more prevalent in patients with mild flu syndrome in COVID-19. It may be a predictor of a good prognosis for this infection. New population-based studies must be carried out to corroborate these findings.
id ABORL-F-1_ce12d39ae7638f34c8025455b919b1dd
oai_identifier_str oai:scielo:S1808-86942022000300439
network_acronym_str ABORL-F-1
network_name_str Brazilian Journal of Otorhinolaryngology
repository_id_str
spelling Olfactory dysfunction in COVID-19: a marker of good prognosis?Olfaction disordersCoronavirus infectionsDysgeusiaSmellAbstract Introduction In May 2020, the World Health Organization recognized olfactory dysfunction as a COVID-19 symptom. The presence of hyposmia/anosmia may be a marker of good prognosis in COVID-19. Objective To associate the presence of olfaction disorder to the clinical condition severity in patients with COVID-19. Methods Individuals with the flu syndrome caused by SARS-CoV-2, diagnosed from March to June 2020, were recruited. They were divided into three groups: mild flu syndrome, severe flu syndrome (admitted to hospital wards) and critical illness (admitted to the ICU). Inpatients were interviewed by telephone contact after hospital discharge and their medical records were also evaluated regarding complementary test results. Outpatients answered an electronic questionnaire containing only clinical information. Results A total of 261 patients participated in the study: 23.75% with mild flu syndrome, 57.85% with severe flu syndrome and 18.40% with critical illness. A total of 66.28% patients with COVID-19 had olfaction disorders. In approximately 56.58% of the individuals the smell alterations lasted between 9 days and 2 months. There was a significantly higher proportion of individuals with olfactory dysfunction in the group with mild flu syndrome than in the severe flu syndrome group (mild × severe - p< 0.001; Odds Ratio = 4.63; 95% CI [1.87-10.86]). This relationship was also maintained between patients with mild flu syndrome and critically-ill patients (mild × critical - p< 0.001; Odds Ratio = 9.28; 95% CI [3.52-25.53]). Conclusion Olfaction dysfunction was significantly more prevalent in patients with mild flu syndrome in COVID-19. It may be a predictor of a good prognosis for this infection. New population-based studies must be carried out to corroborate these findings.Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.2022-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942022000300439Brazilian Journal of Otorhinolaryngology v.88 n.3 2022reponame:Brazilian Journal of Otorhinolaryngologyinstname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)instacron:ABORL-CCF10.1016/j.bjorl.2020.12.002info:eu-repo/semantics/openAccessMendonça,Cindy VitalinoMendes Neto,José ArrudaSuzuki,Fabio AkiraOrth,Marlon SteffensMachado Neto,HugoNacif,Sérgio Robertoeng2022-06-23T00:00:00Zoai:scielo:S1808-86942022000300439Revistahttp://www.bjorl.org.br/https://old.scielo.br/oai/scielo-oai.phprevista@aborlccf.org.br||revista@aborlccf.org.br1808-86861808-8686opendoar:2022-06-23T00:00Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)false
dc.title.none.fl_str_mv Olfactory dysfunction in COVID-19: a marker of good prognosis?
title Olfactory dysfunction in COVID-19: a marker of good prognosis?
spellingShingle Olfactory dysfunction in COVID-19: a marker of good prognosis?
Mendonça,Cindy Vitalino
Olfaction disorders
Coronavirus infections
Dysgeusia
Smell
title_short Olfactory dysfunction in COVID-19: a marker of good prognosis?
title_full Olfactory dysfunction in COVID-19: a marker of good prognosis?
title_fullStr Olfactory dysfunction in COVID-19: a marker of good prognosis?
title_full_unstemmed Olfactory dysfunction in COVID-19: a marker of good prognosis?
title_sort Olfactory dysfunction in COVID-19: a marker of good prognosis?
author Mendonça,Cindy Vitalino
author_facet Mendonça,Cindy Vitalino
Mendes Neto,José Arruda
Suzuki,Fabio Akira
Orth,Marlon Steffens
Machado Neto,Hugo
Nacif,Sérgio Roberto
author_role author
author2 Mendes Neto,José Arruda
Suzuki,Fabio Akira
Orth,Marlon Steffens
Machado Neto,Hugo
Nacif,Sérgio Roberto
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Mendonça,Cindy Vitalino
Mendes Neto,José Arruda
Suzuki,Fabio Akira
Orth,Marlon Steffens
Machado Neto,Hugo
Nacif,Sérgio Roberto
dc.subject.por.fl_str_mv Olfaction disorders
Coronavirus infections
Dysgeusia
Smell
topic Olfaction disorders
Coronavirus infections
Dysgeusia
Smell
description Abstract Introduction In May 2020, the World Health Organization recognized olfactory dysfunction as a COVID-19 symptom. The presence of hyposmia/anosmia may be a marker of good prognosis in COVID-19. Objective To associate the presence of olfaction disorder to the clinical condition severity in patients with COVID-19. Methods Individuals with the flu syndrome caused by SARS-CoV-2, diagnosed from March to June 2020, were recruited. They were divided into three groups: mild flu syndrome, severe flu syndrome (admitted to hospital wards) and critical illness (admitted to the ICU). Inpatients were interviewed by telephone contact after hospital discharge and their medical records were also evaluated regarding complementary test results. Outpatients answered an electronic questionnaire containing only clinical information. Results A total of 261 patients participated in the study: 23.75% with mild flu syndrome, 57.85% with severe flu syndrome and 18.40% with critical illness. A total of 66.28% patients with COVID-19 had olfaction disorders. In approximately 56.58% of the individuals the smell alterations lasted between 9 days and 2 months. There was a significantly higher proportion of individuals with olfactory dysfunction in the group with mild flu syndrome than in the severe flu syndrome group (mild × severe - p< 0.001; Odds Ratio = 4.63; 95% CI [1.87-10.86]). This relationship was also maintained between patients with mild flu syndrome and critically-ill patients (mild × critical - p< 0.001; Odds Ratio = 9.28; 95% CI [3.52-25.53]). Conclusion Olfaction dysfunction was significantly more prevalent in patients with mild flu syndrome in COVID-19. It may be a predictor of a good prognosis for this infection. New population-based studies must be carried out to corroborate these findings.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942022000300439
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942022000300439
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjorl.2020.12.002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
dc.source.none.fl_str_mv Brazilian Journal of Otorhinolaryngology v.88 n.3 2022
reponame:Brazilian Journal of Otorhinolaryngology
instname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron:ABORL-CCF
instname_str Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron_str ABORL-CCF
institution ABORL-CCF
reponame_str Brazilian Journal of Otorhinolaryngology
collection Brazilian Journal of Otorhinolaryngology
repository.name.fl_str_mv Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
repository.mail.fl_str_mv revista@aborlccf.org.br||revista@aborlccf.org.br
_version_ 1754575994981711872